Novartis’ investigational therapy for sickle cell disease (SCD), crizanlizumab (SEG101), was seen to reduce the number of…
Articles by Diogo Pinto
The HRI signaling protein was identified as a key negative regulator of hemoglobin production in red blood cells, unraveling a…
White blood cells were seen to produce molecules that decrease a specific type of hemoglobin — the protein in red blood…
Bluebird bio reported that its investigational gene therapy LentiGlobin showed promising results for severe sickle cell disease (SCD) patients…
Sancilio Pharmaceuticals is reporting that its investigational oral compound Altemia (SC411, docosahexaenoic acid) showed an ability to safely treat sickle…
Global biotechnology company MaxCyte announced the successful correction of a genetic mutation associated with sickle cell disease (SCD) in…